Business Description
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : US8816242098
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 2.69 | |||||
Debt-to-EBITDA | 12.94 | |||||
Interest Coverage | 3.1 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.23 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.4 | |||||
3-Year EPS without NRI Growth Rate | -0.1 | |||||
3-Year FCF Growth Rate | 8.9 | |||||
3-Year Book Growth Rate | -9.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 1 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76.95 | |||||
9-Day RSI | 66.82 | |||||
14-Day RSI | 61.39 | |||||
6-1 Month Momentum % | 57.86 | |||||
12-1 Month Momentum % | 57.5 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.02 | |||||
Quick Ratio | 0.69 | |||||
Cash Ratio | 0.26 | |||||
Days Inventory | 179.18 | |||||
Days Sales Outstanding | 80.45 | |||||
Days Payable | 103.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 10.22 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.24 | |||||
Operating Margin % | 20.14 | |||||
Net Margin % | -3.53 | |||||
FCF Margin % | 5.31 | |||||
ROE % | -7.52 | |||||
ROA % | -1.29 | |||||
ROIC % | 8.33 | |||||
ROC (Joel Greenblatt) % | 6.61 | |||||
ROCE % | 1.28 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 5.39 | |||||
PE Ratio without NRI | 5.48 | |||||
PS Ratio | 0.98 | |||||
PB Ratio | 2.07 | |||||
Price-to-Free-Cash-Flow | 18.33 | |||||
Price-to-Operating-Cash-Flow | 11.37 | |||||
EV-to-EBIT | 80.27 | |||||
EV-to-Forward-EBIT | 20.2 | |||||
EV-to-EBITDA | 20.87 | |||||
EV-to-Forward-EBITDA | 8.82 | |||||
EV-to-Revenue | 2.05 | |||||
EV-to-Forward-Revenue | 2.04 | |||||
EV-to-FCF | 38.87 | |||||
Price-to-Projected-FCF | 1.1 | |||||
Price-to-Median-PS-Value | 1.28 | |||||
Earnings Yield (Greenblatt) % | 1.25 | |||||
FCF Yield % | 5.42 | |||||
Forward Rate of Return (Yacktman) % | 20.24 |